Yousra Izzuddeen1, Subhash Gupta2, K P Haresh1, Dayanand Sharma1, Prashanth Giridhar3, Gour Kishore Rath1. 1. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India. 2. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India. Drsubhash_oncologist@yahoo.in. 3. Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, Badsa, India.
Abstract
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is the most common form of brainstem glioma. The present study was performed to assess if hypofractionated radiotherapy completed in < 3 weeks with temozolomide improves survival in DIPG. MATERIAL AND METHODS: The present study is a phase II open label randomized trial. The study included newly diagnosed patients with DIPG. Patients in arm A received conventional fractionated RT of 60 Gy in 30 fractions over 6 weeks while patients in arm B received hypo-fractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks along with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles. The survival analysis was performed with modified intention to treat analysis. RESULTS: A total of 35 patients were randomized. 33 patients were evaluable. 93% (n = 14) of patients in the conventional arm completed treatment while only 17% (n = 3) of the children could complete planned course of treatment in the experimental arm. The median overall survival (OS) was 11 months (95% CI - 7.5 to 14.5 months) in the conventional arm and 12 months (95% CI - 10.5 to 13.5 months) in the experimental arm (p = 0.208). 28% (n = 5) patients in the experimental arm developed grade 3 or 4 hematological toxicity. CONCLUSION: The above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve OS and has higher hematological toxicity. Conventional radiotherapy remains the standard of care.
RCT Entities:
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is the most common form of brainstem glioma. The present study was performed to assess if hypofractionated radiotherapy completed in < 3 weeks with temozolomide improves survival in DIPG. MATERIAL AND METHODS: The present study is a phase II open label randomized trial. The study included newly diagnosed patients with DIPG. Patients in arm A received conventional fractionated RT of 60 Gy in 30 fractions over 6 weeks while patients in arm B received hypo-fractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks along with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles. The survival analysis was performed with modified intention to treat analysis. RESULTS: A total of 35 patients were randomized. 33 patients were evaluable. 93% (n = 14) of patients in the conventional arm completed treatment while only 17% (n = 3) of the children could complete planned course of treatment in the experimental arm. The median overall survival (OS) was 11 months (95% CI - 7.5 to 14.5 months) in the conventional arm and 12 months (95% CI - 10.5 to 13.5 months) in the experimental arm (p = 0.208). 28% (n = 5) patients in the experimental arm developed grade 3 or 4 hematological toxicity. CONCLUSION: The above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve OS and has higher hematological toxicity. Conventional radiotherapy remains the standard of care.
Authors: David N Korones; Paul G Fisher; Cynthia Kretschmar; Tianni Zhou; Zhengjia Chen; James Kepner; Carolyn Freeman Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Mohamed S Zaghloul; Eman Eldebawy; Soha Ahmed; Amr G Mousa; Amr Amin; Amal Refaat; Iman Zaky; Nada Elkhateeb; Mohamed Sabry Journal: Radiother Oncol Date: 2014-02-20 Impact factor: 6.280
Authors: Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack Journal: Neuro Oncol Date: 2011-02-22 Impact factor: 12.300
Authors: L R Mandell; R Kadota; C Freeman; E C Douglass; J Fontanesi; M E Cohen; E Kovnar; P Burger; R A Sanford; J Kepner; H Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1999-03-15 Impact factor: 7.038
Authors: Valerie Bernier-Chastagner; Jacques Grill; Francois Doz; Serge Bracard; Jean Claude Gentet; A Marie-Cardine; E Luporsi; G Margueritte; O Lejars; V Laithier; F Mechinaud; F Millot; C Kalifa; Pascal Chastagner Journal: Cancer Date: 2005-12-15 Impact factor: 6.860
Authors: Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Hong In Yoon; Chan Woo Wee; Young Zoon Kim; Youngbeom Seo; Jung Ho Im; Yun Sik Dho; Kyung Hwan Kim; Je Beom Hong; Jae Sung Park; Seo Hee Choi; Min Sung Kim; Jangsup Moon; Kihwan Hwang; Ji Eun Park; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Kyoung Su Sung; Jin Ho Song; Min Ho Lee; Myung Hoon Han; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim Journal: Brain Tumor Res Treat Date: 2021-04